On April 26, 2022 Gilead Sciences, Inc. (Nasdaq: GILD) reported that its executives will be speaking at the following investor conferences (Press release, Gilead Sciences, APR 26, 2022, View Source [SID1234612990]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Bank of America Healthcare Conference on Tuesday, May 10 at 5:00pm ET

Bernstein’s Annual Strategic Decisions Conference on Thursday, June 2 at 4:30pm ET

Jefferies Global Healthcare Conference on Wednesday, June 8 at 11:00am ET

Goldman Sachs Global Healthcare Conference on Wednesday, June 15 at 2:20pm ET

The live webcasts can be accessed at the company’s investors page at investors.gilead.com. The replays will be available for at least 30 days following the presentation.

On April 26, 2022 Exelixis, Inc. (Nasdaq: EXEL) reported that its first quarter 2022 financial results will be released on Tuesday, May 10, 2022 after the markets close (Press release, Exelixis, APR 26, 2022, View Source [SID1234612958]). At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update . Access to the event is available via the Internet from the company’s website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call 855-793-2457 (domestic) or 631-485-4921 (international) and provide the conference call passcode 6282616 to join by phone.

A telephone replay will be available until 8:00 p.m. ET on May 12, 2022. Access numbers for the telephone replay are: 855-859-2056 (domestic) and 404-537-3406 (international); the passcode is 6282616. A webcast replay will also be archived on www.exelixis.com for one year.

On April 26, 2022 SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, reported that the Company has launched a Pre-Approval Access/Expanded Access Program ("EAP") with SELLAS’ lead asset, GPS, for treating patients suffering from acute myeloid leukemia (AML) (Press release, Sellas Life Sciences, APR 26, 2022, View Source [SID1234612974]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

GPS is an immunotherapeutic that targets the Wilms Tumor 1 (WT1) protein. The Company is currently testing GPS as a monotherapy in a pivotal Phase 3 clinical trial (the REGAL trial) in patients with AML who have achieved second complete remission, as well as in combination with PD1 inhibitors in earlier stage clinical trials.

"After receiving multiple requests from physicians who have been following GPS and its results to date, it became clear, particularly under the 21st Century Cures Act, that we needed to initiate an EAP quickly to help patients around the world with AML, an aggressive form of cancer that progresses rapidly without the proper treatment," said Angelos Stergiou, MD, ScD. h.c., President and CEO, SELLAS. "SELLAS is firmly committed to its mission to improve clinical outcomes for these patients and their families who want to consider all possible therapeutic options, as well as ensuring that we are bringing a new, safe and potentially effective treatment option to physicians and patients in need."

On April 26, 2022 Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, reported it will report financial results and key pipeline updates for the first quarter ended March 31, 2022 after the U.S. markets close on Monday, May 9, 2022 (Press release, Arcus Biosciences, APR 26, 2022, View Source [SID1234612991]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On April 26, 2022 Symeres reported the acquisition of Organix, a US-based provider of high-quality organic chemistry services (Press release, Symeres, APR 26, 2022, View Source [SID1234612940]). The company is dedicated to the discovery and preclinical stage of the drug-discovery value chain, with a focus on lipids and small molecules. Organix has 47 employees, the majority of which have a PhD in chemistry, and is based in Woburn, in the Boston, MA, area. Its revenue is mainly generated from the sale of specialized and complex organic chemistry research services to biopharma clients.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Symeres and Organix are highly complementary, and the combination unlocks significant strategic value. Organix represents a high-quality foothold into the US market, where Symeres already generates about 40% of its revenues. Furthermore, Organix broadens the Symeres drug-discovery offering into the fast-growing lipids market, addressing mRNA therapeutics and vaccines. Organix’s impressive client list includes some of the world’s leading biopharma companies, many based in the Boston biopharma community. Organix management will remain unchanged; the company is led by Dr. Anu Mahadevan, CEO, and Dr. Paul Blundell.

Symeres CEO Eelco Ebbers is very pleased to quickly integrate Organix into the Symeres group: "Organix is widely known as being highly innovative and an expert organic chemistry services provider that is able to solve complex projects for top-tier clients globally. Joining forces represents a fantastic opportunity for us to expand our drug-discovery-capability offering and provide an exceptional high-quality foothold into the US market."

As the majority shareholder in Symeres, Keensight Capital has worked together with the management team of the two companies to facilitate this combination. Amit Karna, Partner at Keensight Capital, comments: "We are delighted to support Symeres in this exciting acquisition of Organix. We are certain that the resulting business will create a truly differentiated transatlantic offering for the biopharma industry, with significant expertise in molecule design, synthesis, and early-stage clinical manufacturing. Moreover, the scientific and cultural fit of the two organizations could not be more perfect, and we are excited to see what the management teams will achieve together."